Trial
NCT02698111
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Collaborators
—
Condition
Nasopharyngeal Carcinoma
Intervention
Donafenib
Why stopped
Corporate policy adjustments
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-08